Previous 10 | Next 10 |
2024-01-02 23:28:35 ET Summary Orion Group Holdings has achieved a quarterly gross profit of $19.1 million, a 42.5% increase YoY. The company is focusing on improving profitability and has a high backlog of $920 million, exceeding its FY 2022 revenue. Orion Group is divesting ...
2024-01-01 08:00:02 ET Summary In 2023, across two accounts, my portfolios returned +98.4%. In the flagship account, my four-year CAGR (pre-tax), from January 1, 2020 - December 31, 2023, was 46%. This piece discusses what did and didn't work in 2023. What a differen...
2023-12-04 16:40:15 ET Summary The Flagship Account and Smaller Managed Account have performed well year-to-date through November 30, 2023. The blended total return is +71% vs. 4.2% for the Russell 2000. Per Pernas Research, from January 1, 2020 - November 20, 2023, 40.5% of stock...
To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging ...
Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous one To extend its cash runway and continue the ongoing clinical trials in CNS and oncology Initial execution of €8 million in two tranches of €4 million ...
Company on track to report top line data milestone in 1Q 2024 A total of 210 participants have been recruited Multiple primary endpoints include reduction in agitation and aggression and overall BPD disease improvement MADRID, Spain and BOSTON, Nov. 07, 2023 (GLOBE NEW...
BIO-Europe 2023 LSX Investival Showcase 2023 Jefferies London Healthcare Conference 2023 MADRID, Spain and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to d...
2023-10-27 13:00:09 ET More on Industrial Select Sector SPDR ETF A Rising Interest Rate Freight Train Is Coming For The Economy XLI: Industrial Fundamentals Look Great And It's Time To Buy ParaZero, Momentus, ShiftPixy, Luxfer among industrial movers Here are...
Positive aggregate safety data from vafidemstat's fully enrolled PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the drug is safe and well-tolerated Continues to enroll patients in Phase IIb EVO...
2023-10-26 12:54:07 ET Orion Group Holdings, Inc. (ORN) Q3 2023 Earnings Conference Call October 26, 2023 9:00 am ET Company Participants Margaret Boyce - Investor Relations Travis Boone - President & CEO Scott Thanisch - Executive Vice President & CFO ...
News, Short Squeeze, Breakout and More Instantly...
Orion Group Holdings Inc. Common Company Name:
ORN Stock Symbol:
NYSE Market:
Orion Group Holdings Inc. Common Website:
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...
HOUSTON, July 24, 2024 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”), a leading specialty construction company, today reported its financial results for the second quarter ended June 30, 2024. Highlights for the quarter ended June 30, 2024: ...
MADRID and CAMBRIDGE, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received “Deci...